The goal of the study is to learn what happens to MK-4482 after single and multiple dosesin healthy Chinese participants over time. Researchers also want to learn about thesafety of MK-4482, including how well people tolerate it.
Not Provided
Drug: MK-4482
Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day
1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours
(Q12H) on Day 1 through Day 6 for11 doses.
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a Body Mass Index (BMI) of 19 to 24 weight (kg)/height (m)2, inclusive, and body
weight of ≥ 50 kg at the screening visit.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a history of clinically significant abnormalities or diseases.
- Has history of cancer.
- Has a history of significant multiple and/or severe allergies.
- Had any major surgery.
- Has participated in another investigational study within 3 months prior to the
screening visit.
Peking University Third Hospital (Site 0001)
Beijing 1816670, Beijing Municipality 2038349, China
Medical Director, Study Director
Merck Sharp & Dohme LLC